Randall A. Lipps - 01 Dec 2025 Form 4 Insider Report for OMNICELL, INC. (OMCL)

Role
CHAIRMAN, PRESIDENT AND CEO, Director
Signature
/s/ Eric G. Lehmann, Attorney-in-Fact for Randall Lipps
Issuer symbol
OMCL
Transactions as of
01 Dec 2025
Net transactions value
-$233,568
Form type
4
Filing time
03 Dec 2025, 16:05:14 UTC
Previous filing
18 Nov 2025
Next filing
17 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LIPPS RANDALL A CHAIRMAN, PRESIDENT AND CEO, Director OMNICELL, INC., 4220 NORTH FREEWAY, FORT WORTH /s/ Eric G. Lehmann, Attorney-in-Fact for Randall Lipps 03 Dec 2025 0001227556

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OMCL Common Stock Options Exercise $782,525 +28,250 +7.3% $27.70 414,898 01 Dec 2025 Direct F1
transaction OMCL Common Stock Sale $1,016,093 -28,250 -6.8% $35.97 386,648 01 Dec 2025 Direct F1, F2
holding OMCL Common Stock 355,861 01 Dec 2025 In Trust with Wife F3
holding OMCL Common Stock 8,051 01 Dec 2025 In Trust for Children F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OMCL Stock Option NQ (Right to Buy) Options Exercise $0 -28,250 -100% $0.000000 0 01 Dec 2025 Common Stock 28,250 $27.70 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2025.
F2 The price reported in Column 4 is a weighted average price of $35.9679. The sold price range between $35.65 to $36.4746. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Shares held in trust with Mr. Lipps' wife.
F4 Shares held in trust for the benefit of Mr. Lipps' children.
F5 The options were granted on 2/4/2016 with 25% vested on the one-year anniversary of the grant date and the reaming amount vesting ratably over a 36 month period. The options were fully vested on 2/4/2020.